



BIOSENSORS  
INTERNATIONAL

## NEWS RELEASE

### BIOSENSORS ANNOUNCES START OF ENROLLMENT IN BEACON II DRUG-ELUTING STENT REGISTRY

Singapore, 3 March 2008. Biosensors International Group Ltd, (“Biosensors”, “Company”, Bloomberg: BIG SP), today announced the start of enrollment in the BEACON<sup>1</sup> II registry program which plans to enroll 1,000 patients in 15 centers across Asia, including Singapore, Malaysia, Indonesia, Thailand, Australia, and New Zealand. A registry program enlists clinicians to document the performance of a specific therapy for a particular disease or condition. In BEACON II, clinicians will collect and analyze “real-world” use and clinical performance of the BioMatrix™ Drug-Eluting Stent that are implanted in patients in paid-procedures performed by cardiologists at the participating centers.

Professor Koh Tian Hai, Medical Director, Singapore National Heart Center, who is the co-Principal Investigator, implanted the first patient in the BEACON II registry last Friday.

“BEACON II is a follow-on registry to BEACON, a prospective, multi-national, multi-center registry assessing patients treated with the BioMatrix™ drug-eluting stent. BEACON enrolled more than 290 patients at 10 centers in Asia, “said Ms Jane Gau, Vice President of Clinical Research. “By enrolling real-world patients in BEACON II, we will be able to further affirm BioMatrix’s clinical performance in more complex cases that represent more realistically the cases that are presented to physicians on a day-to-day basis.”

Biosensors announced the clinical results of BEACON at the Transcatheter Cardiovascular Therapeutics 2007 (“TCT”) conference, held in Washington D.C., US in October 2007 that showed BioMatrix demonstrated safety and effectiveness based on the 12-month data that reported a 2.1 percent rate of target vessel revascularization and 6.5 percent Major Adverse Cardiac Events (“MACE”) over a 360-day period.

### END OF RELEASE ###

<sup>1</sup> BEACON is an acronym referring to Biolimus Eluting A-9 Coronary stent Obviating Luminal Narrowing

#### **Media Relations & Investor Relations Biosensors International Group**

Mr. Loh Chee Mun  
Senior Vice President  
Tel: (65) 6213 5708  
Email: [cm.loh@biosensors.com](mailto:cm.loh@biosensors.com)

#### **Media Relations / Investor Relations Firm United States**

Allen & Caron Inc.  
Mr. Matt Clawson  
Executive Vice President, Investor Relations  
Tel: (1) 949 474 4300  
Email: [matt@allencaron.com](mailto:matt@allencaron.com)

#### **About Biosensors International Group, Ltd**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate drug-eluting stent programs, BioMatrix<sup>®</sup>, Axxion™, and BioFreedom™, a completely polymer-free drug-eluting stent.

For more information, please visit [www.biosensors.com](http://www.biosensors.com).

#### **About BioMatrix<sup>®</sup>**

BioMatrix<sup>®</sup> offers the unique combination of an innovative anti-restenotic drug, Biolimus A9<sup>®</sup>, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability. Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately leaving in place a biocompatible stent surface.

Biosensors will initiate several post marketing surveillance registries on the BioMatrix stent in April collecting data on over 5000 patients with five year follow-up.

For more information, please visit [www.biomatrix.com](http://www.biomatrix.com)

#### **Forward-Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*